Journal article
Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
- Abstract:
-
Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, but only ∼50% of patients respond. A response only manifests after many months of treatment and is transient. The reasons underlying AZA resistance are unknown, and few alternatives exist for non-res...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Contributors
Beck, D
+ Woll, PS
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
Weatherall Insti. of Molecular Medicine
Funding
National Institute for Health Research
More from this funder
Bloodwise UK
More from this funder
Swedish Research Council
More from this funder
Cancer Society in Stockholm
More from this funder
Swedish Cancer Society
More from this funder
Bibliographic Details
- Publisher:
- Cell Press Publisher's website
- Journal:
- Cell Reports Journal website
- Volume:
- 20
- Issue:
- 3
- Pages:
- 572-585
- Publication date:
- 2017-07-18
- Acceptance date:
- 2017-06-22
- DOI:
- ISSN:
-
2211-1247
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:709350
- UUID:
-
uuid:3ff95b3b-7a63-40de-a9e5-c7ea6efd67e4
- Local pid:
- pubs:709350
- Source identifiers:
-
709350
- Deposit date:
- 2017-08-10
Terms of use
- Copyright holder:
- Unnikrishnan et al
- Copyright date:
- 2017
- Notes:
-
Copyright © 2017 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record